Merck (010683053) Stock Overview

Operates as a healthcare company worldwide. More details

010683053 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	6/6

Rewards

Trading at 66.3% below our estimate of its fair value

Earnings are forecast to grow 8.48% per year

Earnings have grown 12.2% per year over the past 5 years

Pays a high and reliable dividend of 4.12%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

010683053 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Merck & Co., Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Merck
Historical stock prices
Current Share Price	US$63.42
52 Week High	US$0
52 Week Low	US$0
Beta	0.38
1 Month Change	0%
3 Month Change	0.42%
1 Year Change	-35.03%
3 Year Change	-25.70%
5 Year Change	-22.49%
Change since IPO	60.97%

Recent updates

Shareholder Returns

	010683053	CH Pharmaceuticals	CH Market
7D	0%	-0.5%	0.2%
1Y	-35.0%	29.0%	11.6%

Return vs Industry: 010683053 underperformed the Swiss Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: 010683053 underperformed the Swiss Market which returned -2.8% over the past year.

Price Volatility

Is 010683053's price volatile compared to industry and market?
010683053 volatility
010683053 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	3.9%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	7.2%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: 010683053's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine 010683053's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
010683053 fundamental statistics
Market cap	CHF 156.50b
Earnings (TTM)	CHF 13.08b
Revenue (TTM)	CHF 50.74b

12.0x

P/E Ratio

3.1x

P/S Ratio

Is 010683053 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
010683053 income statement (TTM)
Revenue	US$63.62b
Cost of Revenue	US$14.37b
Gross Profit	US$49.25b
Other Expenses	US$32.84b
Earnings	US$16.41b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 30, 2025

Earnings per share (EPS)	6.57
Gross Margin	77.41%
Net Profit Margin	25.79%
Debt/Equity Ratio	72.2%

How did 010683053 perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

49%

Payout Ratio

Does 010683053 pay a reliable dividends?

See 010683053 dividend history and benchmarks

When do you need to buy 010683053 by to receive an upcoming dividend?
Merck dividend dates
Ex Dividend Date	Sep 15 2025
Dividend Pay Date	Oct 07 2025
Days until Ex dividend	112 days
Days until Dividend pay date	90 days

Does 010683053 pay a reliable dividends?

See 010683053 dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/27 01:56
End of Day Share Price	2025/06/30 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merck & Co., Inc. is covered by 49 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Charles Butler	Barclays
Luisa Hector	Berenberg

Merck (010683053) Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

Novartis

Roche Holding

Galderma Group

Sandoz Group

Price History & Performance

Recent News & Updates

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Recent updates

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Health Canada Approves KEYTRUDA for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours That Are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined with Radiotherapy with or Without Cisplatin Then as Monotherapy

Merck Announces Positive Topline Results from the Phase 3 KEYTRUDA Trial in Patients with Muscle-Invasive Bladder Cancer

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

Merck Declares Fourth-Quarter 2025 Dividend, Payable on October 7, 2025

Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Dynamic Index

Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus

Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Merck Manuals Launches AI-Powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

FDA Approves Merck's Anti-PD-1 Therapy

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Merck Announces Positive Topline Results from the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia

Merck Reportedly Held Talks to Buy MoonLake for over $3B

Merck's Investigational Zilovertamab Vedotin at 1.75 mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients with Relapsed/Refractory DLBCL in Phase 2 Portion of Waveline-003 Trial

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Research on Novel Treatment Approaches and Scientific Advances from Merck's Broad and Differentiated Oncology Portfolio and Pipeline to Be Presented at ASCO 2025

Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth Disorders

Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™

Merck & Co., Inc.'s Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmaceuticaletics Compared to Intravenous (IV) KEYTRUDA®? (Pembrolizumab) in Pivotal 3475A-D77 Trial

European Commission Approves Merck's Capvaxive®? (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Merck Data At Acc.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease